Mostrando 10 resultados de: 23
Filtros aplicados
Subtipo de publicación
Other(23)
Área temáticas
Farmacología y terapéutica(17)
Enfermedades(9)
Bioquímica(4)
Medicina y salud(3)
Funcionamiento de bibliotecas y archivos(2)
Origen
google(23)
Antitumor activity of the novel oral highly selective Wee1 inhibitor Debio 0123
OtherAbstract: Background: The Wee1 tyrosine kinase is activated upon DNA damage and regulates the G2-M cell cyclePalabras claves:Autores:Harrison CastroFuentes:googleDevelopment and pre-clinical assessment of a first-in-class small molecule inhibitor of FLIP
OtherAbstract: Evasion of cell death is a major cause of resistance to anti-cancer therapies, making proteins thatPalabras claves:Autores:Harrison CastroFuentes:googleDevelopment and preclinical evaluation of unique first-in-class small molecule inhibitors of the anti-apoptotic protein FLIP
OtherAbstract: In cancer, evasion of cell death is a fundamental cause of resistance to therapy, prompting the devePalabras claves:Autores:Harrison CastroFuentes:googleDevelopment of first-in-class small molecule inhibitors of FLIP which activate caspase-8, the nodal regulator of apoptosis, necroptosis and pyroptosis
OtherAbstract: Caspase-8 is the initiator caspase for the extrinsic apoptotic pathway and now recognized as the molPalabras claves:Autores:Harrison CastroFuentes:googleAbstract B17: Development of novel, potent orally available Wee1 inhibitors with robust antitumor efficacy in vivo
OtherAbstract: Wee1 is a tyrosine kinase that phosphorylates cyclin-dependent kinase 1 (CDC2) to inactive the CDC2/Palabras claves:Autores:Harrison CastroFuentes:googleAbstract C5: FLIP protein-protein interaction inhibitors enhance sensitivity of colorectal cancer cells to chemotherapy and TRAIL
OtherAbstract: Background Colorectal Cancer (CRC) is the second most common cause of cancer death, with 40% of patiPalabras claves:Autores:Harrison CastroFuentes:googleAbstract CT023: Phylogenetic tracking and minimal residual disease detection using ctDNA in early-stage NSCLC: A lung TRACERx study
OtherAbstract: Introduction Minimal residual disease (MRD) detection in solid tumors describes isolation of circulaPalabras claves:Autores:Harrison CastroFuentes:googleAbstract LB-037: Development and preclinical assessment of a first-in-class small molecule inhibitor of the major cell death regulator protein FLIP
OtherAbstract: Background Evasion of cell death is a major cause of resistance to cancer therapy, making proteins tPalabras claves:Autores:Harrison CastroFuentes:googleAbstract LB-049: Targeting the ubiquitin-proteasome system by small molecule inhibition of the DUBome
OtherAbstract: The current interest in protein homeostasis as a therapeutic strategy has highlighted the importancePalabras claves:Autores:Harrison CastroFuentes:googleAbstract LB-054: FKBPL as a novel therapeutic target and prognostic biomarker in high grade serous ovarian cancer
OtherAbstract: FKBPL is a secreted protein with well-established anti-angiogenic and anti-cancer stem cell activityPalabras claves:Autores:Harrison CastroFuentes:google